Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays
- PMID: 16767554
- PMCID: PMC2778700
- DOI: 10.1007/s10165-006-0481-7
Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays
Abstract
Antibodies against prothrombin are detected by enzyme immunoassays (EIA) in sera of patients with antiphospholipid syndrome (APS). However, there are two methods for antiprothrombin EIA; one that uses high binding plates (aPT-A), and another that utilizes phosphatidylserine bound plates (aPS/PT). We aimed to evaluate and compare aPT-A and aPS/PT in a clinical setting. We performed EIA for anti-PT, anti-PS/PT, IgG, and IgM anticardiolipin antibodies (aCL), and IgG beta2-glycoprotein I-dependent aCL (abeta2GPI/CL) with serum samples from 139 systemic lupus erythematosus (SLE) patients (16 with history of at least one thrombotic episode) and 148 controls. We observed that: (1) although titers of anti-PT and anti-PS/PT were significantly related with each other (P < 0.0001, rho = 0.548), titer of anti-PT and anti-PS/PT differed greatly in some samples; (2) odds ratio and 95% confidence interval for each assay was 3.556 (1.221-10.355) for aPT-A, 4.591 (1.555-15.560) for aPS/PT, 4.204 (1.250-14.148) for IgG aCL, 1.809 (0.354-9.232) for IgM aCL, and 7.246 (2.391-21.966) for abeta2GPI/CL. We conclude that, while all EIA performed in this study except IgM aCL are of potential value in assessing the risk of thrombosis, aPS/PT and abeta2GPI/CL seemed to be highly valuable in clinical practice, and that autoantibodies detected by anti-PT and anti-PS/PT are not completely identical.
Figures


Similar articles
-
The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.J Rheumatol. 2001 Dec;28(12):2637-43. J Rheumatol. 2001. PMID: 11764209
-
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome.Clin Chem Lab Med. 2015 Jul;53(8):1265-70. doi: 10.1515/cclm-2014-1129. Clin Chem Lab Med. 2015. PMID: 25562605
-
Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients.Thromb Res. 2014 Mar;133(3):451-4. doi: 10.1016/j.thromres.2013.12.001. Epub 2013 Dec 7. Thromb Res. 2014. PMID: 24342537
-
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review.Thromb Haemost. 2014 Feb;111(2):354-64. doi: 10.1160/TH13-06-0509. Epub 2013 Oct 31. Thromb Haemost. 2014. PMID: 24172938
-
[Phosphatidylserine-dependent anti-prothrombin antibody as a new marker for the diagnosis of antiphospholipid syndrome].Rinsho Byori. 2006 Mar;54(3):256-62. Rinsho Byori. 2006. PMID: 16637574 Review. Japanese.
Cited by
-
Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins.PLoS Pathog. 2021 Dec 3;17(12):e1010118. doi: 10.1371/journal.ppat.1010118. eCollection 2021 Dec. PLoS Pathog. 2021. PMID: 34860860 Free PMC article.
-
The thrombophilic network of autoantibodies in celiac disease.BMC Med. 2013 Apr 4;11:89. doi: 10.1186/1741-7015-11-89. BMC Med. 2013. PMID: 23556408 Free PMC article.
-
New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.Curr Rheumatol Rep. 2014 May;16(5):415. doi: 10.1007/s11926-014-0415-x. Curr Rheumatol Rep. 2014. PMID: 24609824
-
Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss.Clin Exp Immunol. 2008 Dec;154(3):332-8. doi: 10.1111/j.1365-2249.2008.03774.x. Epub 2008 Sep 23. Clin Exp Immunol. 2008. PMID: 18826497 Free PMC article.
-
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.Curr Rheumatol Rep. 2017 Jul;19(7):43. doi: 10.1007/s11926-017-0668-2. Curr Rheumatol Rep. 2017. PMID: 28711993 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous